Author name: Leonardo Arias

Whether happening in public or private, biopharma M&A is fiercer than ever. Experts point to patent pressures, herd mentality and a declining stock of available biotechs with mature assets.

Poor grades assigned by the nonprofit watchdog to the Tenet hospitals in Florida were based on methodology that “has no scientific basis” and “misrepresents hospital safety,” a federal judge ruled.

The Scientia deal follows Medtronic’s announcement in February that it’ll acquire CathWorks for up to $585 million.

The research initiative is part of a broader focus on wearables at the Department of Health and Human Services.

Industry and FDA representatives have reached a general agreement on planned pre-submission facility meetings but have expressed different views about the specifics.

The senator, who has long advocated for expanding access to experimental therapies, reportedly called the FDA’s request for a sham surgery–controlled Phase 3 trial for uniQure’s Huntington’s disease gene therapy “bureaucratic idiocy.”

Artificial intelligence is swiftly evolving, forcing regulators to figure out how to oversee a technology that can act autonomously and potentially improve itself, experts said at the HIMSS conference in Las Vegas.

The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.

Stylus Medicine, a member of BioSpace’s NextGen Class of 2026, launched in May 2025 to develop new, less complex genetic medicines. The company’s in vivo approach has attracted “intense” interest from Big Pharma.

Breakout Ventures’ focus on early-stage companies stands out as more and more investors elect to save their dollars for derisked assets.